Sensus Healthcare Company Profile: SRTS Business, Executives & Facts

Current data has a 15-minute delay. Please / to get real-time quotes.

Summary

Options

Financials

News

Filings

Profile

Key StatisticsCurrency:USD

EPS(TTM)

0.41

P/E(TTM)

11.54

BVPS

3.38

P/B

1.37

Revenue(2024 Q4)

13.07M

YoY

3.97%

Net Income(2024 Q4)

1.55M

YoY

-63.28%

Gross Margin(TTM)

58.44%

Net Margin(TTM)

15.90%

ROE(TTM)

12.70%

Debt ratio

10.20%

Dividend Yield(TTM)

Payout Ratio

Profile

Sensus Healthcare, Inc.

 A medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions 

Sensus Healthcare, Inc., a Delaware limited liability company, was formed on May 7, 2010. The company is a medical device company dedicated to providing highly effective, non-invasive, cost-effective treatments for both neoplastic and non-neoplastic skin conditions. Using a proprietary low-energy X-ray technology known as superficial radiation therapy (" SRT "), which is based on more than ten years of dedicated research and development, the company has successfully incorporated SRT into a portfolio of therapeutic devices: SRT-100TM, SRT-100 + TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat both neoplastic and non-neoplastic skin diseases in hundreds of thousands of patients worldwide.

Related Sections

H
Health Care Equipment & Supplies+1.11%
H
Healthcare Equipment+0.99%

Revenue BreakdownCurrency:USD

Data source:2024 FY

Total

41.81M

Name

Revenue

Proportion

Product

36.65M

87.65%

Service

5.16M

12.35%

Major shareholders

Edwin L. Solot, Jr.

Joseph C. Sardano

DividendsCurrency:USD

No Data

Net Income Attributable to Parent

Total Cash Dividends

Payout Ratio

Institutional Holdings

Totally

institutions reported their ownerships on

SRTS

Institutional Holding Ratio

Price

Insider Transactions

Net increase

Net decrease

Price

Executive Profile

Feedback

Disclaimer: All data and information presented above are from third-party data sources. They are for reference only and do not constitute any investment advice.

Market Data Risk Disclosure|Privacy Policy

You Can Understand Stocks with AI.

Why NVDA surged 16.40%?

Because it

AInvest

Aime Coplilot

Invest Smarter With AI Power.

Open App